WELTON


Associated tags: Pharma, Solubility, Other Manufacturing, API, Generic drug, Water, Colorectal cancer, Patient, Patent, Cancer, Acceleration, Research, Oncology, Science, Pharmaceutical, Health, Biotechnology, Manufacturing, Plastics, Chemicals, Lubrizol

Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic

Retrieved on: 
Tuesday, June 20, 2023
Other Manufacturing, Research, Chemicals, Plastics, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Oncology, Acceleration, API, Cancer, Multimedia, Solubility, Patent, Patient, Colorectal cancer, Water, Generic drug, Lubrizol

The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton).

Key Points: 
  • The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton).
  • The license allows Welton to use the Apisolex excipient worldwide to develop and commercialize a novel formulation of SN-38 to treat colorectal and associated gastro-intestinal cancers.
  • Combining Welton’s formulation expertise and Lubrizol’s Apisolex excipient, Welton plans to develop a novel formulation of SN-38 to overcome its solubility challenges in water, which has hindered its clinical development.
  • Welton seeks to develop a stable, ready-to-use formulation having higher bioavailability and shorter infusion time to enhance the clinical outcome for cancer patients.